Literature DB >> 10628373

Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis.

M Maruyama1, T Nagahama, Y Yuasa.   

Abstract

BACKGROUND: CPT-11 is an effective antitumor agent for gastrointestinal malignancy, but the optimum route of administration is unclear.
METHODS: Intraperitoneal administration of this agent was compared with intravenous administration in mouse models for peritoneal seeding and liver metastasis. The peritoneal seeding model and liver metastasis model were respectively established by inoculation of colon 26 tumor cells into the peritoneal cavity and spleen of female BALB/c mise. CPT-11 (40 mg/kg) was injected intraperitoneally or intravenously on days 2 and 5 after inoculation of tumor cells.
RESULTS: Intraperitoneal administration of CPT-11 was significantly more effective than intravenous administration for control of both peritoneal seeding and liver metastasis.
CONCLUSION: Intraperitoneal administration of CPT-11 may be a more efficient form of adjuvant chemotherapy for prevention of both peritoneal seeding and liver metastasis in patients with gastrointestinal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628373

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Preclinical antitumor activity of a nanoparticulate SN38.

Authors:  Mazin F Al-Kasspooles; Stephen K Williamson; David Henry; Jahna Howell; Fengui Niu; Charles J Decedue; Katherine F Roby
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

2.  Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.

Authors:  Byung-Jin Ahn; Moon Ki Choi; Young Suk Park; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Jae-Wook Ko; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2010-09-09       Impact factor: 2.953

3.  Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.

Authors:  Nadine Leonie de Boer; Alexandra R M Brandt-Kerkhof; Eva V E Madsen; Marjolein Diepeveen; Esther van Meerten; Ruben A G van Eerden; Femke M de Man; Rachida Bouamar; Stijn L W Koolen; Ignace H J T de Hingh; Checca Bakkers; Koen P Rovers; Geert-Jan M Creemers; Maarten J Deenen; Onno W Kranenburg; Alexander Constantinides; Ron H J Mathijssen; Cornelis Verhoef; Jacobus W A Burger
Journal:  BMJ Open       Date:  2019-12-08       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.